Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Accenture
McKesson
US Department of Justice
Dow
Federal Trade Commission
Harvard Business School
Merck
Julphar

Generated: December 13, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PHENPROCOUMON

« Back to Dashboard

Clinical Trials for Phenprocoumon

Trial ID Title Status Sponsor Phase Summary
NCT00528671 Very Low Dose Oral Anticoagulation and Thromboembolic and Bleeding Complications Terminated Klinikum Ludwigshafen Phase 4 We aim to investiagte whether very low dose self management of oral anticoagulation is superior to low dose oral anticoagulation in order to prevent bleeding events in patients undergoing mechanuical heart valve replacement.
NCT00528671 Very Low Dose Oral Anticoagulation and Thromboembolic and Bleeding Complications Terminated University of Kiel Phase 4 We aim to investiagte whether very low dose self management of oral anticoagulation is superior to low dose oral anticoagulation in order to prevent bleeding events in patients undergoing mechanuical heart valve replacement.
NCT00528671 Very Low Dose Oral Anticoagulation and Thromboembolic and Bleeding Complications Terminated Heart and Diabetes Center North-Rhine Westfalia Phase 4 We aim to investiagte whether very low dose self management of oral anticoagulation is superior to low dose oral anticoagulation in order to prevent bleeding events in patients undergoing mechanuical heart valve replacement.
NCT00586287 Study to Find Out the Appropriate Initial Dose of the Anticoagulant Drug Phenprocoumon Completed Cantonal Hospital of St. Gallen Phase 4 Oral anticoagulation is often initiated in hospitalized patients. Although the therapeutic range of phenprocoumon is narrow, the individual drug demands unfortunately vary greatly between persons. Our group recently developed two dosing algorithms for the initiation of anticoagulation based on clinical predictors such as age, gender, body weight and laboratory values. The aim of the proposed study is to prospectively evaluate the efficacy and safety of these two algorithms in medical and orthopedic inpatients, as well as in a group of outpatients and possibly in a geriatric collective.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Phenprocoumon

Condition Name

Condition Name for Phenprocoumon
Intervention Trials
Atrial Fibrillation 14
Acute Coronary Syndrome 4
Pulmonary Embolism 2
Malignant Melanoma, Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Phenprocoumon
Intervention Trials
Atrial Fibrillation 17
Thrombosis 6
Pulmonary Embolism 4
Embolism 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Phenprocoumon

Trials by Country

Trials by Country for Phenprocoumon
Location Trials
Germany 22
United States 7
Switzerland 3
Netherlands 3
Austria 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Phenprocoumon
Location Trials
Virginia 1
Texas 1
Tennessee 1
Pennsylvania 1
New York 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Phenprocoumon

Clinical Trial Phase

Clinical Trial Phase for Phenprocoumon
Clinical Trial Phase Trials
Phase 4 12
Phase 3 5
Phase 2 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Phenprocoumon
Clinical Trial Phase Trials
Recruiting 8
Completed 7
Terminated 4
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Phenprocoumon

Sponsor Name

Sponsor Name for Phenprocoumon
Sponsor Trials
Boehringer Ingelheim 3
German Atrial Fibrillation Network 3
Medical University of Vienna 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Phenprocoumon
Sponsor Trials
Other 30
Industry 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Queensland Health
Mallinckrodt
US Department of Justice
Johnson and Johnson
Harvard Business School
Baxter
UBS
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.